Summary
10.82
0.14
(1.26%)
07/21/2026
Kura Oncology, Inc. (KURA)Key Facts
Performance
Historical returns1D
1.26%
1W
-4.98%
1M
n/a
3M
9.20%
6M
24.19%
1Y
65.07%
5Y
-42.46%
Snapshot
Key statisticsClose
10.82
Change
0.14
Change %
1.26%
Open
10.63
Day Range
10.49 – 10.88
Volume
820,550
Avg Vol (20d)
1,689,768
Rel Vol
0.49x
52W Range
5.45 - 12.49
vs 52W High
-13.41%
vs 52W Low
98.44%
Gap
0.02
Market Cap
USD 895.03M
Beta
0.23
Price Chart
Advanced chartCompareLast 730 data points are shown. To view all data, Upgrade to PRO plan!
New Highs
Historical highs| Period | New Highs | From Last |
|---|---|---|
| 5-Day | 0× | -4.55% |
| 1-Month | 7× | -10.77% |
| 3-Month | 9× | -10.77% |
| 6-Month | 10× | -10.77% |
| YTD | 4× | -10.77% |
| Period | New Highs | From Last |
|---|---|---|
| 52-Week | 21× | -10.91% |
| 2-Year | 0× | -50.23% |
| 3-Year | 21× | -54.04% |
| 5-Year | 14× | -54.04% |
| 10-Year | 66× | -74.01% |
Financial SnapshotFY 2025
Full financialsRevenue
USD 67.48M
+25.2% YoY
Net Income
-USD 278.67M
+60.2% YoY
EPS
-3.18
+57.4% YoY
Gross Margin
99.9%
Operating Margin
-449.9%
Net Margin
-412.9%
EBITDA
-USD 275.83M
Free Cash Flow
-USD 70.70M
-104.8% margin
ROE
-160.0%
ROA
-37.7%
Debt / Equity
0.12x
net debt -USD 128.64M
Cash & Equiv.
USD 149.10M
Fundamental Ratings
MainC
RecommendedSell
DCFBuy
ROEStrong Sell
ROAStrong Sell
Debt/EquitySell
P/EStrong Sell
P/BStrong Sell
Latest Earnings
- KURA reported last earnings on 2026-05-12.
- EPS of $-0.83 vs $-0.88 estimated — surprise $0.05.
- Revenue of $18M vs $26M estimated — surprise $-8M.
News
All newsKura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib's Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026
– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve, advanced ccRCC patients –
Kura Oncology: A Menin Inhibitor Launch With More Than One Way To Win
Kura Oncology is positioning ziftomenib (KOMZIFTI) as a combination backbone in AML, not just a relapsed/refractory monotherapy. KURA's robust cash position, bolstered by Kyowa Kirin payments, is expected to fund the pivotal KOMET-017 trial through the topline readout in 2028. Recent combination...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, July 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on July 1, 2026, the Compensation Committee of the Company's...
Kura Oncology, Inc. (KURA) Discusses Long-Term Results of Ziftomenib Combination Therapies in Newly Diagnosed and Relapsed/Refractory AML Transcript
Kura Oncology, Inc. (KURA) Discusses Long-Term Results of Ziftomenib Combination Therapies in Newly Diagnosed and Relapsed/Refractory AML Transcript
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –
Kura Oncology, Inc. (KURA) Discusses Clinical Data and Updated Development Strategy for Darlifarnib Transcript
Kura Oncology, Inc. (KURA) Discusses Clinical Data and Updated Development Strategy for Darlifarnib Transcript
Kura Oncology Highlights Darlifarnib's Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy
– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients –
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose – – Central MRD negativity in 75% of CRc responders with no prior venetoclax exposure; median CRc duration was 9.2 months – – Median OS not...
Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients –
Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA) today announced its participation in the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Kura management is scheduled to participate in a virtual fireside chat at 1:30 p.m. ET / 10:30 a.m. PT on...
Kura Oncology, Inc. (KURA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Kura Oncology, Inc. (KURA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Kura Oncology, Inc. (KURA) Q1 2026 Earnings Call Transcript
Kura Oncology, Inc. (KURA) Q1 2026 Earnings Call Transcript
Kura Oncology Q1 Earnings Call Highlights
Kura Oncology NASDAQ: KURA reported $5.8 million in first-quarter net product revenue from KOMZIFTI, its first commercial product, and said the launch is showing early signs of physician uptake, broad payer coverage and use in combination regimens, according to management's earnings call for the...
Kura Oncology (KURA) Reports Q1 Loss, Tops Revenue Estimates
Kura Oncology (KURA) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to a loss of $0.66 per share a year ago.
Kura Oncology Reports First Quarter 2026 Financial Results
– $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching and combination adoption, reflect strong early momentum – – Broad and rapid payer access...
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
– Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML –
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Bank of America Securities 2026 Healthcare Conference. Kura...
Kura Oncology to Report First Quarter 2026 Financial Results
SAN DIEGO, May 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report first quarter 2026 financial results after the close of U.S. financial...